Venture funding for life science companies plummets in Q2, says report
This article was originally published in Scrip
US venture capital investment in life science companies declined for the fourth quarter in a row – a predictable drop considering the limitations on exit strategies – plunging 39% on a year-over-year basis during the second quarter of 2012 while VC dollars across all industries fell just 12% in the same timeframe.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.